26 results about "Drug tolerance" patented technology

The invention relates to the technical field of clinical medical data visualization, in particular to a visualization system for clinical internal medicine and a visualization method thereof. The method comprises the following steps: acquiring basic information of a clinical patient; according to the basic information of the clinical patient, performing medical treatment and medication event analysis, and performing triple entity relationship processing to generate patient medical record relationship map data; performing patient drug tolerance analysis based on the patient medical record relation map data to generate patient drug tolerance characteristic data; performing clinical physiological index risk probabilistic reasoning according to the drug tolerance characteristic data of the patient to generate individual clinical medication risk data; according to the individual clinical medication risk data, individual characteristic medicine dosage adjustment is carried out, medicine dosage curve visual dynamic display is carried out, and visual clinical medication response data is generated. According to the method, personalized and visual medication decision support is provided for clinicians through patient medication conditions and real-time physiological index analysis.

The invention belongs to the technical field of biological detection, and particularly relates to a rapid detection method and a micro-fluidic chip for rapid detection. The existing detection method and instrument have the problems of long detection time, incapability of detecting unknown pathogenic bacteria and the like, and cannot meet the timeliness requirement of clinical application. According to the scheme, rapid detection of the drug resistance of bacteria is realized by detecting the growth state of high-throughput single bacteria, and the method comprises the following steps: culturing the bacteria by using the micro-fluidic chip designed in the invention, capturing the single bacteria through a single bacteria capturing channel, and continuously growing in the channel; and obtaining a morphological change matrix of single bacteria evolved along with time in each bacteria capture channel, carrying out statistical analysis to obtain a bacteria phenotype index, and further obtaining the drug tolerance condition of the bacteria on the basis of index numerical value change. According to the method, the function of rapidly detecting the drug resistance of various common clinical pathogenic bacteria within 2 hours can be realized.

The invention discloses an application of a medicine cobimetinib (cobimetinib) in inhibiting the activity of a YAP-TEAD transcription complex, and relates to the field of medicine application. The invention relates to an application of cobimetinib (cobimetinib) and sorafenib (sorafenib) in the prevention of the drug tolerance of the liver cancer to the sorafenib (sorafenib) through the combined use of the cobimetinib and the sorafenib (sorafenib). According to the cobimetinib disclosed by the invention, the cobimetinib can be used for inhibiting the occurrence and the development of YAP highly activated tumors by targeting a YAP-TEAD transcription complex, so that the adaptation disease range of the cobimetinib is expanded; according to the present invention, the activity of the YAP is inhibited through the cobimetinib in the targeting manner, such that the drug tolerance of the liver cancer on the sorafenib can be prevented;

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

The invention relates to a drug sustained release microsphere for injection and a preparation method thereof. The preparation is a sustained-release microsphere injection, the prepared microspheres are narrower in particle size distribution, high in encapsulation efficiency and small in burst release rate, the drug can be continuously released for four weeks to six weeks, a better administration route is provided for patients with poor gastrointestinal absorption, and meanwhile, the drug tolerance and toxic and side effects can be reduced. The preparation method comprises the following steps: adding a cosolvent, and adjusting the proportion of a medicinal active component and a biocompatible high polymer material in an organic solvent, the mass percentage of the cosolvent and the organic solvent, the mass percentage concentration of a surfactant in an external water phase, and the proportion of the mass of the organic solvent and the mass of the external water phase, so as to prepare the biocompatible high polymer material. The microsphere preparation containing the active pharmaceutical ingredients is obtained in an emulsification mode, the burst release rate in vitro within 24 hours is lower than 10%, the encapsulation efficiency is high, the preparation method is simple, and the microsphere preparation can be suitable for industrialization of the production process of the microsphere preparation.

The application discloses a traditional Chinese medicine composition for preventing and treating chicken Bordetella, a preparation method and application thereof. The traditional Chinese medicine composition for preventing and treating chicken Bordetella comprises the following raw medicinal materials in parts by weight: one red 15-20 parts, Tianwen grass 15-20 parts, goldenrod 10-15 parts, Jixiang grass 10-15 parts, white yam 5-12 parts, Buddha's hand 5-12 parts and platycodon 5-10 parts. The traditional Chinese medicine composition adopts one red, Tianwen grass, goldenrod, Jixiang grass, white yam, Buddha's hand and platycodon for reasonable compounding, has the effects of clearing heat and cooling blood, relieving cough and asthma, and can effectively treat chicken Bordetella disease. The seven kinds of medicines are mixed to prepare an oral liquid, the seven kinds of medicines have a synergistic effect in the preparation process, the effects of the medicines are effectively exerted, and the effects of clearing heat and detoxifying, clearing heat and cooling blood, relieving cough and asthma are further enhanced. The composition is scientifically matched, has no obvious toxic side reaction and drug tolerance, and can provide a train of thought for solving the problem of antibiotic resistance.

The present invention relates to the field of pharmaceutical detection technology. The present invention provides a method for detecting anti-recombinant human GLP-1-Fc fusion protein antibodies, comprising: (1) acidifying and incubating a sample to be tested, and then neutralizing it; (2) adding a working solution containing a biotin-labeled GLP-1 fusion protein and a GLP-1 fusion protein labeled with an electrochemiluminescent substance to the reaction solution after neutralization in step (1), and incubating the mixture; (3) adding the reaction solution after incubation in step (2) to a microplate coated with streptavidin, sealing the plate, incubating the plate, and then washing the plate; (4) adding a plate reading buffer to the microplate after washing in step (3), and performing electrochemiluminescence detection; the method has high sensitivity and a high drug tolerance level.

The application discloses a Toxoplasma SRS29C and ROP16 double-gene deletion strain and a construction method and application thereof, relates to the technical field of parasite genetic engineering and molecular biology. The Toxoplasma SRS29C and ROP16 double-gene deletion strain is obtained by knocking out SRS29C and ROP16 genes of the ME49 strain through a CRISPR / Cas9 system. The double-gene deletion strain constructed by the application has drug sensitivity change (sensitivity to ethidium bromide), growth defect phenotype, and only carries a single screening marker, and under in-vitro culture conditions, the double-gene deletion strain presents a significant slow growth trend, and the number of worm-containing bubbles is obviously less than that of the wild type and single-gene deletion strain. The double-gene deletion strain substantially influences the proliferation of the worm body, and provides key data support for exploring the molecular basis of the double-gene deletion leading to the increase of the drug sensitivity of the worm body and for analyzing the regulation mechanism of the drug tolerance related path of the Toxoplasma.

The invention provides a tolerance evaluation system and method for medicines in an intelligent medicine box, and the method comprises the steps: extracting a medication behavior feature vector and a physiological feature vector from the weight change data of the medicines in the intelligent medicine box and a physiological signal after a target patient takes medicines, and determining the fusion features of the tolerance evaluation of the medicines; recognizing the dependency relationship between the medication event of the target patient and the physiological signal according to the fusion feature and the metabolic half-life period of the drug; combining the drug metabolism data of the target patient with a knowledge graph of drug action in the intelligent drug box to determine drug tolerance feature nodes of the target patient in the drug use process; and determining a drug tolerance tensor when the target patient takes drugs according to the tolerance feature node in combination with the dependency relationship, and generating a drug tolerance evaluation map according to the drug tolerance tensor and the current metabolic data of the target patient. According to the technical scheme provided by the invention, the dynamic association between the medication event of the target patient and the continuous physiological metabolism response in the drug tolerance evaluation can be identified.

The invention relates to the field of pharmaceutical preparations, in particular to a sotalol hydrochloride spray composition and a preparation method thereof.The sotalol hydrochloride spray composition comprises 2.5-5.0 parts of sotalol hydrochloride, 0.005-0.03 part of a solubilizer, 0.01-0.05 part of a stabilizer, 0.01-0.05 part of a preservative and 10.0-30.0 parts of a solvent.The composition can effectively improve the drug effect of sotalol hydrochloride and meanwhile improve the drug tolerance of patients. In addition, the invention also provides a preparation method of the sotalol hydrochloride spray composition with high drug loading capacity, and the method is simple and convenient in process operation, high in production efficiency and suitable for industrial production.

The invention discloses a BVLD-REDV bifunctional polypeptide modified nickel-titanium alloy and a preparation method of the BVLD-REDV bifunctional polypeptide modified nickel-titanium alloy. According to the preparation method, two functional polypeptides, namely BVLD and REDV, are used for carrying out functional modification on the surface of the nickel-titanium alloy, and an anticoagulant polypeptide BVLD and an endothelial cell specific polypeptide REDV are covalently grafted to the surface of the nickel-titanium alloy, so that the compatibility between a stent prepared from the nickel-titanium alloy and a blood vessel environment in a living body is improved. The design of the double-functional surface of the intravascular stent prepared from the nickel-titanium alloy modified by the double-functional polypeptide is expected to have the advantages in the aspects of improving biocompatibility, reducing adverse events such as restenosis in the stent, preventing thrombosis and the like. According to the dual-functional intravascular stent, the two polypeptides with different functions are covalently fixed on the surface of the nickel-titanium alloy substrate, so that the problem that drugs are exposed to the whole body of a patient and the drug tolerance problem possibly exists is effectively avoided, and the risk of adverse reaction generated when the stent is implanted into the human body is reduced.

The present invention provides a pharmaceutical composition for preventing and / or treating neuropathic pain or complications, wherein the active ingredients of the pharmaceutical composition include an artemisinin compound and pregabalin, wherein the artemisinin compound is selected from one or more of dihydroartemisinin, artemether and artesunate, preferably dihydroartemisinin. The combined use of dihydroartemisinin and pregabalin of the present invention has obvious advantages in treating the core symptoms of neuropathic pain, reducing drug side effects and reducing drug tolerance.

The invention provides a nerve-soothing and sleep-aiding compound for improving sleep quality and application of the nerve-soothing and sleep-aiding compound. The nerve soothing and sleep aiding compound for improving sleep quality comprises the following components in parts by weight: 10-30 parts of a spina date seed extract, 5-15 parts of a polygala tenuifolia extract, 2-5 parts of sandalwood, 2-3 parts of bergamot, 2-3 parts of corydalis tuber, 1-2 parts of albizia flower, 1-2 parts of chamomile, 2-3 parts of lavender, 3-5 parts of sweet orange and 8-20 parts of a poria cocos extract. According to the nerve-soothing and sleep-aiding compound for improving the sleep quality and the application thereof, the nerve-soothing and sleep-aiding compound adopts various natural plant extracts and functional components, is safe and free of side effects, does not generate drug dependence and drug resistance after being used for a long time, is suitable for being used by people with various sleep disorders, and is free of toxic and side effects. According to the compound, through the synergistic effect of various components, the sleep time can be remarkably shortened, the sleep time can be prolonged, the sleep depth can be improved, the sleep quality can be effectively improved, and the compound has a good improvement effect on sleep disorders caused by pressure, anxiety and the like.

The present invention relates to the technical field of biomedicine, and particularly relates to an HER2-targeting polypeptide-drug conjugate, and a preparation method therefor and the use thereof. The polypeptide-drug conjugate provided in the present invention has good in-situ self-assembly performance in vivo, can bind to HER2 and increase the drug concentration in a tumor area by means of self-assembly at the target site, promotes drug endocytosis, and releases the drug in response to enzyme cleavage in lysosomes, thereby treating tumors having either high or low HER2 expression. In addition, the HER2-targeting polypeptide-drug conjugate provided in the present invention has the property of overcoming HER2 ADC drug tolerance.

According to the invention, the level of the anti-Teprotumumab antibody in human serum is detected by adopting an electrochemical luminescence analysis method. The method comprises the following steps: carrying out pretreatment on a sample in a treatment mode of taking Teprotumumab antibody protein as a capture protein and acidifying and diluting with an acid solution, taking ruthenium-labeled Teprotumumab antibody protein as a detection protein, then carrying out electrochemical luminescence detection, and judging whether the Teprotumumab antibody exists in the sample to be detected according to a light intensity signal value. The method established by the invention has high sensitivity and better drug tolerance, and compared with the existing detection method, the method has obvious technical improvement.

The invention discloses an analysis method for detecting an FGF21 anti-drug antibody in serum based on ELISA (Enzyme-Linked Immunosorbent Assay). The analysis method comprises the following steps: (1) carrying out detection through the ELISA; (2) a screening critical value SCPFloating is obtained, the SCPFloating is equal to MCF * Mean (NC), and an estimated multiplication correction factor MCF is equal to Median (S / N) + 1.645 * 1.4826 * MAD (S / N); and (3) a confirmation critical value CCPFloating is obtained, wherein CCPFloating is equal to Median (SIR%) + 2.326 * 1.4826 * MAD (SIR%), and CCPFloating is equal to Median (SIR%) + 2.326 * 1.4826 * MAD (SIR%). The method has the advantages of simple operation, accurate screening and confirmation, high sensitivity and appropriate drug tolerance concentration, and is suitable for analyzing the FGF21 anti-drug antibody in serum.

The present invention provides a composite drug for treating osimertinib-resistant non-small cell lung cancer, belonging to the field of biomedicine technology. Osimertinib combined with SR11302 inhibits the proliferation of drug-resistant cells and reduces the drug resistance of cells, so that the IC of cells to osimertinib is reduced. 50 The combined use of SR1302 and osimertinib decreased the expression of ERBB2, ERBB3, p-AKT, and p-ERK1 / 2; in mouse experiments, the combined use of osimertinib and SR11302 significantly inhibited tumor growth. This suggests that combined therapy may be an effective strategy to overcome osimertinib resistance and can provide more effective treatment options for NSCLC patients.

The invention provides an STAT3 inhibitor and application of the STAT3 inhibitor. The STAT3 inhibitor is prepared from psoralen, isopsoralen, salidroside and quercetin. Wherein the psoralen, the isopsoralen, the salidroside, the quercetin and other small molecule ligand compounds can inhibit A549 cell proliferation, are concentration-dependent, and have statistical significance; the psoralen, the isopsoralen, the salidroside and the quercetin are extracted from natural traditional Chinese medicinal materials, so that the psoralen, the isopsoralen, the salidroside and the quercetin are good in drug tolerance and very small in side effect.

The invention discloses a traditional Chinese medicine formula for improving sleep and a preparation method thereof, and relates to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 15-25 parts of semen ziziphi spinosae, 10-20 parts of flos albiziae, 10-20 parts of caulis polygoni multiflori, 5-11 parts of semen boitae, 5-11 parts of rhizoma acori graminei, 5-15 parts of radix polygalae, 1-7 parts of liquorice root, 3-9 parts of lavender, 2-8 parts of oat, 2-8 parts of herba ecliptae, 0.05-0.15 part of resveratrol and 0.5-1.5 parts of vitamin E. According to the traditional Chinese medicine formula for improving sleep and the preparation method of the traditional Chinese medicine formula, the pure natural traditional Chinese medicine formula is used for replacing chemically synthesized hypnotics, components such as benzodiazepine and non-benzodiazepine which are prone to generating dependency are completely not contained, sleep aiding is achieved by adjusting natural rhythms of neurotransmitters and biological clocks, and drug tolerance accumulation and abstinence reaction are avoided.

2-piperidyl or 2-pyrazolyl substituted pyrimidine compounds represented by formula (I) or pharma- ceutically acceptable salts, isotopic substitutes, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof, pharmaceutical compositions comprising said compounds, and uses of said pharmaceutical compositions in the treatment of diseases mediated by EGFR protein and its mutants. TIFF2025502559000208.tif5256(I)

The present disclosure relates to a drug for preventing and / or treating glaucoma. Specifically, provided in the present disclosure is the use of an adenosine A2A receptor antagonist in the treatment and prevention of glaucoma. The treatment and prevention include, but are not limited to, inhibiting aqueous humor production in non-pigmented epithelial cells of the ciliary body, reducing elevated intraocular pressure caused by the obstruction of aqueous humor outflow due to fibrosis and thickening of the trabecular meshwork, improving the fluidity of aqueous humor in the eye, inhibiting pathological changes in the trabecular meshwork, and achieving a protective effect on retinal cells. Additionally, the drug of the present disclosure may also help to reduce the problem of drug tolerance in the treatment of glaucoma, can lower intraocular pressure in glaucoma patients and provide a protective effect on optic nerves, and provides a more effective strategy for long-term treatment.

The present invention relates to the field of medicine, and specifically to the application of cinnamaldehyde in the preparation of a drug for improving the tolerance of nitrate drugs, a pharmaceutical composition and a preparation thereof. The inventor of the present application creatively discovered that cinnamaldehyde can solve the problem that nitroglycerin is easy to produce tolerance in the prior art, prolong the action time of nitroglycerin, and reduce the dosage of nitroglycerin, which not only expands the clinical application of nitroglycerin, but also expands the benefits, and is more in line with the current level of the pharmaceutical industry and the current status of pharmaceutical investment from the principle of pharmaceutical economics. Experimental results confirm that for experimental subjects who have developed nitroglycerin tolerance, the combined use of cinnamaldehyde and nitroglycerin has a vasodilation effect that is nearly 10% higher than the vasodilation maximum degree Emax of the vascular ring when nitroglycerin is used alone, and even if a lower nitroglycerin dosage is used, a better vasodilation effect can still be achieved, indicating that cinnamaldehyde can be used for the preparation of drugs for improving the tolerance of nitrate drugs.

This invention discloses a nucleic acid delivery vector, its preparation method, and its applications, belonging to the field of drug delivery vector technology. The nucleic acid delivery vector provided by this invention is based on the LNP structure, retaining key lipids or lipid-like substances unchanged. By altering the surface composition of the LNP, it can effectively reduce the accumulation of LNP in the liver, achieving effective in-situ mRNA delivery and protein expression; thereby significantly improving LNP organ toxicity, reducing mRNA drug side effects, and enhancing mRNA drug tolerance; it achieves in-situ targeting and high nucleic acid expression by promoting in-situ uptake of the vector and enhancing endosome escape; by optimizing various components and parameters or adding active lipids, the in-situ expression level and stability of the prepared nucleic acid delivery vector can be enhanced; after use, sonication of the application site can also promote the in-situ expression level of the nucleic acid delivery vector.

The invention discloses an analysis method for detecting a GLP-1 drug-resistant antibody in serum based on ELISA (Enzyme-Linked Immunosorbent Assay), which is used for analyzing and verifying a screening critical value, a confirmation critical value, a titer critical value, sensitivity, drug tolerance, a hook effect and the like. A screening critical value, a confirmation critical value and a titer critical value are determined reasonably, the precision is high, the sensitivity is high, the drug tolerance is proper, the hook effect is avoided under high concentration, the selectivity is high, and the method is suitable for analyzing the anti-drug antibody of the GLP-1 in the serum.

The application discloses application of rapamycin in preparation of a reliever of opiate drug tolerance caused by an anti-angiogenic drug, the reliever and a medicine, and relates to the technical field of medicine application. It is found that a TSC1-mTOR-autophagy axis plays a role in opiate drug tolerance caused by an anti-angiogenic drug, and the specific embodiment is that the anti-angiogenic drug can cause a decrease in TSC1 content, an mTOR / RPS6 pathway is activated, thereby autophagy flow is blocked, and pain sensation is enhanced; therefore, the opiate tolerance condition can be relieved by adjusting the mTOR / RPS6 pathway through rapamycin.

The present invention relates to a pharmaceutical composition for inhibiting anticancer drug tolerance, recovering anticancer drug responsiveness, or enhancing anticancer drug sensitivity, the composition containing an ODC1 inhibitor as an active ingredient. More specifically, it was found that if ODC1 expression or activity is inhibited when inducing EGFR-targeting drug tolerance using a non-small cell lung cancer cell model overexpressing a kinase involved in EGFR-targeting drug tolerance induction and an animal model xenografted with same, the acquisition of EGFR-targeting drug tolerance caused by kinase overexpression is inhibited and the tolerance is alleviated, and thus drug responsiveness is recovered. Therefore, an agent that inhibits the ODC1 expression or activity can be effectively used as an effective ingredient in a pharmaceutical composition for inhibiting anticancer drug tolerance, recovering anticancer drug responsiveness, or enhancing anticancer drug sensitivity.